CNS THERAPEUTICS XCHANGE
EAST COAST 2023
Boston
May 24, 2023

Welcome to hubXchange’s CNS Therapeutics Xchange East Coast 2023, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in developing CNS therapies.

Discussion topics will cover Novel Targets, Preclinical, Clinical Studies and Drug Delivery.

Take advantage of this unique highly interactive meeting format designed for maximum engagement, collaboration and networking with your peers.

Please note this is an In-Person meeting.

VENUE DETAILS: Hilton Boston Woburn Hotel, 2 Forbes Road, Woburn MA 01801

SNAPSHOTS OF DISCUSSION TOPICS

Track 1: Novel Targets

Novel therapies for complex neurological disorders: discovery of effective treatments
Opportunities from emerging therapeutic modalities: Target selection in an evolving druggability landscape

Track 2: Preclinical

Methods to increase the success rates of drugs entering clinical phases
Novel strategies for reverse translation of temporal biomarkers for CNS drug development
Relevant in vitro mechanistic profiling to guide SAR and downstream in vivo studies

Track 3: Clinical Studies

Utilizing clinical biomarkers to enhance drug development in neurodegenerative diseases
Are circulating neurodegeneration biomarkers ready for prime time?
Fluid and digital biomarkers in neurodegenerative disorders

Track 4: Drug Delivery

Transcytosis-mediated brain delivery for proteins, antibodies, oligonucleotides, and small molecules
Non-invasive methods to increase brain drug uptake

Full Xchange Agenda

Click on each track for detailed agenda

Novel Targets

Time

Titles and Bullets

Facilitator

08:00 – 08:30

Registration

08:30 – 09:00

Opening Address & Keynote Presentation

09:05 – 10:05

Novel therapies for complex neurological disorders: discovery of effective treatments

Brian Pfister

Vice President – Global Medical Affairs, Praxis Precision Medicines

10:10 – 10:40

1-2-1 Meetings/Networking Break

10:40 – 11:10

1-2-1 Meetings / Networking Break

11:10 – 11:20

Morning Refreshments

11:10 – 11:20

Morning Refreshments

11:20 – 12:20

Sponsor-led Roundtable

12:20 – 13:20

Networking Lunch

13:20 – 13:50

Spotlight Presentation

13:55 – 14:25

1-2-1 Meetings / Networking Break

14:25 – 14:55

1-2-1 Meetings / Networking Break

15:35 – 16:35

Opportunities from emerging therapeutic modalities: Target selection in an evolving druggability landscape

Ziv Kirshner

R&D Director of Advanced Analytical Sciences, Noveome Biotherapeutics, Inc.

16:35 – 16:45

Afternoon Refreshments

17:45 – 18:45

Evening Drinks Reception

Preclinical

Time

Titles and Bullets

Facilitator

08:00 – 08:30

Registration

08:30 – 09:00

Opening Address & Keynote Address

09:05 – 10:05

Methods to increase the success rates of drugs entering clinical phases

Philip Iredale

Vice President, Head of Biology, Cerevel Therapeutics

Phil did his PhD and a brief post doc in signal transduction mechanisms in CNS at the University of Nottingham in the UK. In 1994 he joined the Duman/Nestler lab at Yale investigating the molecular regulation of CRF receptors and, exploring the role the receptor plays in withdrawal from drugs of abuse. He joined Pfizer in 1997 as a lab head where he took on increasingly senior roles leading several programs incuding CB1 agonists/antagonists, psychosis disease space. In 2004 he joined the CNS management team and subsequently headed several programs in neuroscience, neurology and external collaborations which led to therapeutic area operational oversight as well as Kendall Sqauare MA site responsibilities. In 2018 Pfizer announced that it was exiting Neuroscience. Phil subsequently joined Cerevel Therapeutics as Head of Biology in October of 2018.

10:10 – 10:40

1-2-1 Meetings / Networking Break

10:40 – 11:10

1-2-1 Meetings / Networking Break

11:10 – 11:20

Morning Refreshments

12:20 – 13:20

Networking Lunch

13:20 – 13:50

Spotlight Presentation

13:55 – 14:25

1-2-1 Meetings / Networking Break

14:25 – 14:55

1-2-1 Meetings / Networking Break

15:35 – 16:35

Novel strategies for reverse translation of temporal biomarkers for CNS drug development

Murali Gopalakrishnan

Global Head, Neuroscience Search & Evaluation, AbbVie

16:35 – 16:45

Afternoon Refreshments

16:45 – 17:45

Relevant in vitro mechanistic profiling to guide SAR and downstream in vivo studies

Not having the right in vitro assay, or relying heavily on a single work-horse assay can lead to:
- Low quality hit rate from HTS (low confirmation)
- Not tractable SAR
- Unable to improve SAR
- SAR moving in the wrong direction
- Selecting the wrong molecule into in vivo
Should we invest more resources for deeper mechanistic profiling (kinetics, signaling pathways, etc.)? Or should we move molecules into in vivo models ASAP?

Sokhom S. Pin

Director, Head of In Vitro Pharmacology, Cerevel

Sokhom Pin is currently the head of in vitro pharmacology at Cerevel Therapeutics, where his team is engaged in exploring novel targets, assay development/screening, as well as mechanistic profiling of late-stage molecules. Prior to Cerevel, he built and lead a similar team at Alkermes, Inc.. Sokhom has over 20 years of drug discovery experience at large and mid-sized pharma’s, including DuPont, BMS, and Novartis. He has a strong passion is GPCR pharmacology and neuroscience drug discovery. He received his Ph.D. in Pharmaceutical Sciences (Pharmacology/Toxicology) from the University of Connecticut and his M.S. from the Johns Hopkins University.

17:45 – 18:45

Evening Drinks Reception

Clinical Studies

Time

Titles and Bullets

Facilitator

08:00 – 08:30

Registration

08:30 – 09:00

Opening Address & Keynote Presentation

09:05 – 10:05

Utilizing clinical biomarkers to enhance drug development in neurodegenerative diseases

Pallavi Sachdev

Executive Director, Translational Medicine, Eisai US

10:10 – 10:40

1-2-1 Meetings / Networking Break

10:40 – 11:10

1-2-1 Meetings / Networking Break

11:10 – 11:20

Morning Refreshments

11:20 – 12:20

Sponsor-led Roundtable

12:20 – 13:20

Networking Lunch

13:20 – 13:50

Spotlight Presentation

13:55 – 14:25

1-2-1 Meetings / Networking Break

14:25 – 14:55

1-2-1 Meetings / Networking Break

15:35 – 16:35

Are circulating neurodegeneration biomarkers ready for prime time?

Inflammation: what is the state of the art of inflammation-based biomarkers in AD? We can measure in animal models but how well are we able to precisely monitor brain markers of brain inflammation in humans?
Synapse function: what are the most reliable markers of synapse architecture, function and integrity? Are these being deployed in human trials?
Everything else: what have we learned from targeting Abeta after all these decades? We cured mice with AD but not people so clearly there is a disconnected – lets discuss. Are there other yet-to-be-studied markers or mechanisms associated with Abeta signaling, accumulation or plaque formation?

Chad Beyer

Chief Executive Officer, Kures

Chad Beyer is CEO of Kures and formerly CEO and Head of R&D at Promentis Pharmaceuticals. Dr. Beyer has 25 years of experience in biotech fundraising and the development of novel, disease-modifying medications. Prior to Promentis, Dr. Beyer was the SVP of R&D at Ariel Pharmaceuticals and Head of Neurochemistry at Wyeth Pharmaceuticals. Dr. Beyer contributed to the commercialization of two blockbuster medications and holds a Ph.D. in neuropharmacology from LSU Medical Center and an MBA from the Rutgers Business School. He has served on the Board of Directors of several companies, authored more than 70 manuscripts, and is the Entrepreneur in Residence at Lafayette College.

16:35 – 16:45

Afternoon Refreshments

16:45 – 17:45

Fluid and digital biomarkers in neurodegenerative disorders

Brendan Hare

Associate Director, Medical Affairs, Click Therapeutics

17:45 – 18:45

Canape/Drinks Reception

Drug Delivery

Time

Titles and Bullets

Facilitator

08:00 – 08:30

Registration

08:30 – 09:00

Opening Address & Keynote Presentation

09:05 – 10:05

Transcytosis-mediated brain delivery for proteins, antibodies, oligonucleotides, and small molecules

Susan Rosenbaum

Founder, Chairman & Chief Executive Officer, Lauren Sciences LLC

10:10 – 10:40

1-2-1 Meetings / Networking Break

10:40 – 11:10

1-2-1 Meetings / Networking Break

11:10 – 11:20

Morning Refreshments

11:20 – 12:20

Sponsor-led Roundtable

12:20 – 13:20

Networking Lunch

13:20 – 13:50

Spotlight Presentation

13:55 – 14:25

1-2-1 Meetings / Networking Break

14:25 – 14:55

1-2-1 Meetings / Networking Break

15:35 – 16:35

Non-invasive methods to increase brain drug uptake

Gabriele Proetzel

Senior Director, External Neuroscience Innovation Neuroscience Drug Discovery Unit, Takeda

16:35 – 16:45

Afternoon Refreshments

17:45 – 18:45

Canape/Drinks Reception

CNS THERAPEUTICS XCHANGE
EAST COAST 2023
Boston
May 24, 2023